A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

Disclosed herein are biomaterial implants, medical devices, or bioprostheses wherein a surface or part thereof is coated with a nanoreservoir comprising a hydrophilic polymer or copolymer backbone crosslinked to a second polymer comprising a hydrophilic backbone and one or more reactive moieties, wherein the nanoreservoir further comprises one or more bioactive molecules, therapeutic molecules, or drugs.

Disclosed herein are biomaterial implants, medical devices, or bioprostheses wherein a surface or part thereof is coated with a nanoreservoir comprising a hydrophilic polymer or copolymer backbone crosslinked to a second polymer comprising a hydrophilic backbone and one or more reactive moieties, wherein the nanoreservoir further comprises one or more bioactive molecules, therapeutic molecules, or drugs.

The invention provides a polymerizable composition and a hydrogel obtained or obtainable from the polymerizable composition. The polymerizable composition comprises cucurbituril and a first monomer having a guest for the cucurbituril, wherein the total monomer concentration, C.sub.mon, within the polymerizable composition is at least 0.5 M. The composition may be an aqueous composition.

The invention provides a polymerizable composition and a hydrogel obtained or obtainable from the polymerizable composition. The polymerizable composition comprises cucurbituril and a first monomer having a guest for the cucurbituril, wherein the total monomer concentration, C.sub.mon, within the polymerizable composition is at least 0.5 M. The composition may be an aqueous composition.

The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer comprising side chain-linked amino acids functionalized at their alpha-amino group by a reactive azide moiety by means of which the payload molecules are coupled to the copolymer. The copolymer is typically further functionalized to contain a single copy of a cell type- or tissue type-specific targeting moiety.

The present disclosure relates to the delivery of multiple copies of a payload molecule such as an active agent or a chelating agent capable of capturing an active agent, using as a carrier for their delivery a biocompatible copolymer comprising side chain-linked amino acids functionalized at their alpha-amino group by a reactive azide moiety by means of which the payload molecules are coupled to the copolymer. The copolymer is typically further functionalized to contain a single copy of a cell type- or tissue type-specific targeting moiety.

An electrochemical catch-release system (1) for repeated use comprising pH-responsive polymers (2) covalently linked to a structure (3) via a monolayer (4) of eletrochemically insensitive aryl bonds, forming a polyelectrolyte arrangement (5), the polyelectrolyte arrangement (5) being arranged to, when the covalently bounded polymers (2) are in a neutral state, catch an entity (6) being a protein, a vesicle, or a compound modified with poly(ethylene glycol) by non-electrostatic interactions e.g. hydrogen bonds, and when the polymers (2) are in a charged state, release by electrostatic repulsion an entity (6) captured by the polyelectrolyte arrangement (5). The system also comprising a device (7) for applying an electrochemical potential to the polyelectrolyte arrangement (5) to induce a switch of the polyelectrolyte arrangement (5) from the neutral state to the charged state or the reverse in the presence of redox active species.

An electrochemical catch-release system (1) for repeated use comprising pH-responsive polymers (2) covalently linked to a structure (3) via a monolayer (4) of eletrochemically insensitive aryl bonds, forming a polyelectrolyte arrangement (5), the polyelectrolyte arrangement (5) being arranged to, when the covalently bounded polymers (2) are in a neutral state, catch an entity (6) being a protein, a vesicle, or a compound modified with poly(ethylene glycol) by non-electrostatic interactions e.g. hydrogen bonds, and when the polymers (2) are in a charged state, release by electrostatic repulsion an entity (6) captured by the polyelectrolyte arrangement (5). The system also comprising a device (7) for applying an electrochemical potential to the polyelectrolyte arrangement (5) to induce a switch of the polyelectrolyte arrangement (5) from the neutral state to the charged state or the reverse in the presence of redox active species.

Described herein are therapeutic pH responsive compositions comprising a block copolymer and a therapeutic agent useful for the treatment of cancer.